PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26251572-9	2015	RESULTS: Treatment with the combination of olmesartan medoxomil and amlodipine besylate led to a significant reduction in atherosclerotic lesion size in ApoE(-/-) mice (olmesartan medoxomil/amlodipine besylate: 122,277+-6,795 mum(2), number [n]=14; versus control: 177,502+-10,814 mum(2), n=9; P<0.001).	olmesartan	43-53	apolipoprotein E	Mus musculus	153-157	
27562051-1	2016	OBJECTIVE: To investigate the effect and possible mechanisms of olmesartan medoxomil on atherosclerosis of apolipoprotein E knockout (ApoE(-/-)) mice.	olmesartan	64-74	apolipoprotein E	Mus musculus	107-123	
20399087-0	2011	Olmesartan, a novel angiotensin II type 1 receptor antagonist, reduces severity of atherosclerosis in apolipoprotein E deficient mice associated with reducing superoxide production.	olmesartan	0-10	apolipoprotein E	Mus musculus	102-118	
23177972-8	2013	Olmesartan also suppressed dilatation of aortic diameter, although it did not significantly affect the plaque area, in the abdominal aorta in ApoE-deficient mice.	olmesartan	0-10	apolipoprotein E	Mus musculus	142-146	
23124103-2	2012	We have recently demonstrated that the combination therapy with olmesartan (OLM), an angiotensin II receptor blocker, and azelnidipine (AZL), a dihydroprydine calcium-channel blocker, improves endothelial function in diabetic Apolipoprotein-deficient (ApoE(-/-)) mice.	olmesartan	64-74	apolipoprotein E	Mus musculus	252-256	
23124103-2	2012	We have recently demonstrated that the combination therapy with olmesartan (OLM), an angiotensin II receptor blocker, and azelnidipine (AZL), a dihydroprydine calcium-channel blocker, improves endothelial function in diabetic Apolipoprotein-deficient (ApoE(-/-)) mice.	olmesartan	76-79	apolipoprotein E	Mus musculus	252-256	
23124103-10	2012	In conclusion, the combination therapy with OLM and AZL exerts anti-atherogenic effect in diabetic ApoE(-/-) mice through suppression of oxidative stress and activation of eNOS, independent of its blood pressure-lowering effects.	olmesartan	44-47	apolipoprotein E	Mus musculus	99-103	
18344628-8	2007	In conclusion, olmesartan reduced oxidative stress, and attenuated the hypoxia-induced LV remodeling, in part through the inhibition of NF-kappaB and MMP-9 activities, in apoE-KO mice.	olmesartan	15-25	apolipoprotein E	Mus musculus	171-175	
21464389-6	2011	Aortic ring assay revealed that olmesartan-treated ApoE(-/-) mice had a markedly lower angiogenic response than that of untreated ApoE(-/-) mice.	olmesartan	32-42	apolipoprotein E	Mus musculus	51-55	
21464389-7	2011	Bone marrow-derived endothelial progenitor cell-like c-Kit(+) cells from olmesartan-treated ApoE(-/-) mice showed marked impairment of cellular functions and lower expression of TLR2/TLR4 and MMP-2 compared with those of untreated controls.	olmesartan	73-83	apolipoprotein E	Mus musculus	92-96	
20079903-2	2010	Thus, we investigated the effects of an angiotensin II type 1 receptor (AT1) antagonist, olmesartan, on the levels of cathepsins in brachiocephalic atherosclerotic plaque and plaque stabilization in apolipoprotein E (apoE)-deficient mice receiving a high-fat diet.	olmesartan	89-99	apolipoprotein E	Mus musculus	199-215	
20079903-3	2010	Under a high fat diet, treatment with olmesartan (3 mg/kg per day) maintained collagen and elastin at high levels and attenuated the plaque development and cathepsin S (Cat S) level in the atherosclerotic plaque of apoE-deficient mice.	olmesartan	38-48	apolipoprotein E	Mus musculus	215-219